Free shipping on all orders over $ 500

PD-1/PD-L1 Programmed Death-1/Programmed Death-Ligand 1

Cat.No.  Name Information
M8959 BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) BMS-1 (PD-1/PD-L1 inhibitor 1, PD1-PDL1-IN1) is an inhibitor of PD-1/PD-L1 protein/protein interaction with an IC50 of 6 to 100 nM.
M6101 Atezolizumab Atezolizumab (atezolizumab) is a humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 signaling with PD-1 and B7-1 and restores tumor-specific T-cell immunity. However, it does not affect the interaction of PD-L2 with PD-1. MW: 145 KD. atezolizumab reacts with murine PD-L1 (for human and non-humanized mice).
M6100 Nivolumab Nivolumab (nabumab) is a fully humanized IgG4 monoclonal antibody against PD-1. It has immune checkpoint inhibitory activity and antitumor activity; MW: 143.597 KD.(for human-derived mice).
M3813 Avelumab (MSB0010718C) Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Avelumab recognizes murine PD-L1
M40764 Anti-Mouse PD-L1 In vivo
M31384 TPP-1 hydrochloride TPP-1 hydrochloride is a potent inhibitor of PD-1/PD-L1 interaction and binds specifically to PD-L1 with a Kd value of 95 nM.Can be used in tumor related studies.
M31223 BMSpep-57 hydrochloride  BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs.
M29255 BMS-1166 hydrochloride  BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
M29254 BMS-1001 hydrochloride  BMS-1001 hydrochloride is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 hydrochloride exhibits low-toxicity in cells.
M28797 BMS-8  BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1.
M25529 Anti-Mouse PD-1 (CD279) In vivo
M25528 (D) PPA-1 TFA (D) PPA-1 TFA is the first hydrolysisresistant D-peptide antagonists to target the PD-1/PD-L1 pathway. (D) PPA-1 could bind PD-L1 at an affinity of 0.51 μM in vitro.
M21327 Human PD-L1 inhibitor V Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln.
M15101 Cemiplimab Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Cemiplimab blocks T-cell inactivation and boosts the immune system's antitumor response.
M11456 Evixapodlin Evixapodlin (PD-1/ PD-L1-in 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. Evixapodlin has anti-cancer and anti-virus properties.
M11421 AUNP-12 TFA Aunp-12 (NP-12) TFA is a peptide antagonist of the PD-1 signaling pathway, which has an equivalent antagonistic effect on PD-L1 and PD-L2 in terms of inhibiting lymphocyte proliferation and effector function. Aunp-12 TFA has immune-activating effect and good anti-tumor activity, which has the potential to better study immune-related adverse events (irAEs).
M11354 INCB086550 INCB086550 selectively inhibited PD-L1 with IC50 of 3.1 nM, 4.9 nM and 1.9 nM for human, rhesus monkey and rat pD-L1, respectively. INCB086550 could not inhibit the binding of PD-L2 to PD-1 at 10 μM. INCB086550 significantly inhibits the PD-1/PD-L1 signaling axis by binding to PD-L1 protein, leading to PD-L1 dimerization and internalization, and has good tumor suppressive effect in a variety of mouse tumor models.
M10290 BMS-1166 BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor, which binds to human PD-L1 and blocks its interaction with PD-1.
M10288 BMS-1001 Bms-1001 Hydrochloride is orally active and is an inhibitor of the human PD-L1/PD-1 immune checkpoint. Bms-1001 Hydrochloride is characterized by low cytotoxicity.r.
M9416 Durvalumab Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. Durvalumab was inactive against the mPD-L1.

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.